TABLE 3.
Virus family | Mutant | Methylation | Attenuation in cell culturea | Attenuation in animal modelb | Immunogenicityc |
---|---|---|---|---|---|
Paramyxoviridae | rhMPV wild type | WTd | WT | Virulent | WT |
rhMPV G1696A | Defective in 2′-O | Attenuated | Highly attenuated | WT | |
rhMPV G1700A | Defective in 2′-O | Attenuated | Attenuated | WT | |
rhMPV D1755A | Defective in 2′-O | Attenuated | Highly attenuated | WT | |
Rhabdoviridae | rVSV wild type | WT | WT | Virulent | WT |
rVSV G1670A | Lacked G-N-7 but not 2′-O | Attenuated | Low virulence | WT | |
rVSV G1674A | Sensitive to SAM concn | Not attenuated | Virulent | NDe | |
rVSV D1735A | Diminished G-N-7 and 2′-O | Attenuated | ND | ND |
Attenuation was judged by plaque size, infectivity, and growth curve. Data for VSV are from reference 27.
For hMPV, attenuation was judged by viral replication and pathology in nasal turbinate and lung tissue in cotton rats; for VSV, attenuation was judged by clinical symptoms, body weight loss, viral replication, and pathology in lung and brain tissues in mice. Data for VSV are from reference 54.
Immunogenicity was judged by the antibody level and protection rate after challenge with virulent virus.
WT, wild-type level.
ND, not done.